Thank you for the discussion during the global meeting. This token commemorates the occasion. DS3, Strategy & Venturing Major

Systems Manager based in London, UK. Currently supporting IMPACT (Clinical Trials Management System), CART (Spotfire reporting) and Gemstone (Veeva). Previous experience with reporting support in Business Objects and Microstrategy. Have been working at Bayer since 2006. Degree in BSc Computer Science.

Camilla works as System Specialist in Systems Support. Previous work experience as Clinical Records Coordinator and Senior eTMF Specialist.

Tilman is an automation manager, currently taking care of the reporting sub-stream in the Gemstone Ruby project.

My name is Pinky Damani, I'm with Bayer for 14yrs, originally from Mumbai, India, but settled in NJ, USA. I love to play cricket and badminton. Married, 2 children. Currently, working on Spectrum DMW platform with CDSA, Accenture and Oracle, part of Data Transformation and Ingestion Team, I'm very excited and happy to be part of DSA&I. Looking forward to our connect!

Our vision at Data Science Services & Solutions, DS3, is to Enable, Scale, and Operationalize R&D Data Science & AI capabilities to achieve Clinical Research and Development Speed, Efficiency, and Optimization. Learn more about our areas of responsibility, capabilities, strategic priorities, and collaborations. For more information, contact DS3 Head: Abi Velurethu. Artwork created using Stable Diffusion.

The Data Assets and Insights Solutions subfunction, DAIS, consists of a team of dedicated computer and data scientists which combine deep R&D process and domain expertise (biology, chemistry, pharmacy, etc) with advanced computational expertise (software engineering, natural language processing, scalable architectures, bio- & chem-informatics, data integration & visualization, etc). We integrate, enrich and harmonize large scientific datasets to build foundational data assets which are used by the R&D organization and our team to build insights solutions. They address key R&D challenges to improve speed, quality and probability of success of our R&D pipeline. Selected business critical tasks within R&D we are focusing on: - Target identification including holistic assessment - Disease understanding including precision medicine - Pipeline evaluation (therapeutic potential and risks) - Modality selection including identification of tool compounds - Identification of collaboration and in-licensing opportunities For more information contact: Wolfgang Thielemann. Artwork: Licensed pictures.